Hainan Honz Pharmaceutical Co (300086) — Strategic Asset Allocation Index
Hainan Honz Pharmaceutical Co (300086) has a Strategic Asset Allocation Index of 69.5% as of June 2023. Strategic assets (PP&E of CN¥952.86 Million plus long-term investments of CN¥-) total CN¥952.86 Million, measured against net assets of CN¥1.37 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Hainan Honz Pharmaceutical Co net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Hainan Honz Pharmaceutical Co Strategic Asset Allocation Index (2007–2021)
This chart shows how Hainan Honz Pharmaceutical Co's Strategic Asset Allocation Index has evolved across 15 annual periods from 2007 to 2021. As of June 2023, the index stands at 69.5%, representing strategic assets of CN¥952.86 Million against net assets of CN¥1.37 Billion CNY. For live market cap and overall valuation, see market value of Hainan Honz Pharmaceutical Co.
Annual Strategic Asset Allocation Index for Hainan Honz Pharmaceutical Co (2007–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Hainan Honz Pharmaceutical Co from 2007 to 2021, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 300086 net assets for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 63.7% | CN¥989.88 Million | CN¥989.88 Million | CN¥- | CN¥1.55 Billion | ▲ +7.3 pp |
| 2020 | 56.5% | CN¥904.23 Million | CN¥904.23 Million | CN¥- | CN¥1.60 Billion | ▲ +13.9 pp |
| 2019 | 42.6% | CN¥681.81 Million | CN¥681.81 Million | CN¥- | CN¥1.60 Billion | ▲ +2.4 pp |
| 2018 | 40.1% | CN¥663.73 Million | CN¥663.73 Million | CN¥- | CN¥1.65 Billion | ▲ +15.6 pp |
| 2017 | 24.6% | CN¥472.14 Million | CN¥472.14 Million | CN¥- | CN¥1.92 Billion | ▲ +7.2 pp |
| 2016 | 17.4% | CN¥326.04 Million | CN¥326.04 Million | CN¥- | CN¥1.87 Billion | ▼ -1.0 pp |
| 2015 | 18.4% | CN¥338.44 Million | CN¥338.44 Million | CN¥- | CN¥1.84 Billion | ▼ -1.8 pp |
| 2014 | 20.2% | CN¥364.63 Million | CN¥364.63 Million | CN¥- | CN¥1.80 Billion | ▼ -7.3 pp |
| 2013 | 27.5% | CN¥497.86 Million | CN¥497.86 Million | CN¥- | CN¥1.81 Billion | ▲ +1.2 pp |
| 2012 | 26.3% | CN¥493.63 Million | CN¥493.63 Million | CN¥- | CN¥1.87 Billion | ▲ +1.4 pp |
| 2011 | 25.0% | CN¥462.56 Million | CN¥462.56 Million | CN¥- | CN¥1.85 Billion | ▲ +13.1 pp |
| 2010 | 11.8% | CN¥215.90 Million | CN¥215.90 Million | CN¥- | CN¥1.83 Billion | ▼ -34.5 pp |
| 2009 | 46.3% | CN¥111.40 Million | CN¥111.40 Million | CN¥- | CN¥240.49 Million | ▲ +9.3 pp |
| 2008 | 37.0% | CN¥55.69 Million | CN¥55.69 Million | CN¥- | CN¥150.41 Million | ▲ +7.9 pp |
| 2007 | 29.1% | CN¥33.76 Million | CN¥33.76 Million | CN¥- | CN¥115.89 Million | — |